These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 1355678

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. PCR-based CYP2D6 genotyping for Finnish lung cancer patients.
    Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Pelkonen O, Vainio H.
    Pharmacogenetics; 1993 Feb; 3(1):19-27. PubMed ID: 8097947
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer.
    Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Sorsa M, Vainio H.
    Pharmacogenetics; 1992 Dec; 2(6):259-63. PubMed ID: 1306126
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls.
    Sugimura H, Caporaso NE, Shaw GL, Modali RV, Gonzalez FJ, Hoover RN, Resau JH, Trump BF, Weston A, Harris CC.
    Carcinogenesis; 1990 Sep; 11(9):1527-30. PubMed ID: 1976046
    [Abstract] [Full Text] [Related]

  • 10. Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer.
    Wadelius M, Autrup JL, Stubbins MJ, Andersson SO, Johansson JE, Wadelius C, Wolf CR, Autrup H, Rane A.
    Pharmacogenetics; 1999 Jun; 9(3):333-40. PubMed ID: 10471065
    [Abstract] [Full Text] [Related]

  • 11. Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphism.
    Turgeon J, Evans WE, Relling MV, Wilkinson GR, Roden DM.
    Br J Clin Pharmacol; 1991 Sep; 32(3):283-8. PubMed ID: 1685663
    [Abstract] [Full Text] [Related]

  • 12. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
    Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA.
    DNA Cell Biol; 1991 Oct; 10(8):545-58. PubMed ID: 1681816
    [Abstract] [Full Text] [Related]

  • 13. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.
    Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmöller J, Frötschl R, Köpke K, Gerloff T, Chernov JN, Roots I.
    Eur J Clin Pharmacol; 2003 Aug; 59(4):303-12. PubMed ID: 12879168
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes.
    Daly AK, Armstrong M, Monkman SC, Idle ME, Idle JR.
    Pharmacogenetics; 1991 Oct; 1(1):33-41. PubMed ID: 1688241
    [Abstract] [Full Text] [Related]

  • 17. N-acetyltransferase-2, glutathione S-transferase M1, alcohol dehydrogenase, and cytochrome P450IIE1 genotypes in alcoholic liver cirrhosis: a case-control study.
    Rodrigo L, Alvarez V, Rodriguez M, Pérez R, Alvarez R, Coto E.
    Scand J Gastroenterol; 1999 Mar; 34(3):303-7. PubMed ID: 10232877
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Mutant debrisoquine hydroxylation genes in Parkinson's disease.
    Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR.
    Lancet; 1992 Apr 25; 339(8800):1017-8. PubMed ID: 1349052
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.